AtriCure Sees Unusually High Options Volume (ATRC)

Share on StockTwits

AtriCure Inc. (NASDAQ:ATRC) was the target of some unusual options trading on Wednesday. Stock traders purchased 1,000 call options on the company. This is an increase of 1,654% compared to the typical volume of 57 call options.

Several institutional investors have recently bought and sold shares of the company. FMR LLC grew its position in shares of AtriCure by 0.9% during the 3rd quarter. FMR LLC now owns 5,304,261 shares of the medical device company’s stock worth $185,808,000 after buying an additional 48,654 shares during the period. BlackRock Inc. grew its position in shares of AtriCure by 11.4% during the 4th quarter. BlackRock Inc. now owns 3,075,083 shares of the medical device company’s stock worth $94,096,000 after buying an additional 314,841 shares during the period. Vanguard Group Inc grew its position in shares of AtriCure by 4.1% during the 3rd quarter. Vanguard Group Inc now owns 1,588,574 shares of the medical device company’s stock worth $55,647,000 after buying an additional 63,261 shares during the period. Vanguard Group Inc. grew its position in shares of AtriCure by 4.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,588,574 shares of the medical device company’s stock worth $55,647,000 after buying an additional 63,261 shares during the period. Finally, Millennium Management LLC grew its position in shares of AtriCure by 31.0% during the 4th quarter. Millennium Management LLC now owns 877,574 shares of the medical device company’s stock worth $26,854,000 after buying an additional 207,472 shares during the period. Institutional investors own 86.13% of the company’s stock.

ATRC has been the subject of a number of research analyst reports. BidaskClub cut AtriCure from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $39.00 price target on shares of AtriCure in a report on Friday, November 2nd. Finally, Zacks Investment Research cut AtriCure from a “buy” rating to a “hold” rating in a report on Tuesday, January 1st. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $35.60.

Shares of ATRC stock opened at $33.08 on Thursday. The company has a quick ratio of 1.96, a current ratio of 2.62 and a debt-to-equity ratio of 0.31. AtriCure has a 12 month low of $16.96 and a 12 month high of $36.49.

TRADEMARK VIOLATION WARNING: “AtriCure Sees Unusually High Options Volume (ATRC)” was originally published by Macon Daily and is the sole property of of Macon Daily. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://macondaily.com/2019/02/21/atricure-sees-unusually-high-options-volume-atrc.html.

About AtriCure

AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.

Further Reading: Treasury Bonds

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.